172 related articles for article (PubMed ID: 32145382)
1. Factors influencing safety and efficacy of intravenous iron-carbohydrate nanomedicines: From production to clinical practice.
Nikravesh N; Borchard G; Hofmann H; Philipp E; Flühmann B; Wick P
Nanomedicine; 2020 Jun; 26():102178. PubMed ID: 32145382
[TBL] [Abstract][Full Text] [Related]
2. Critical nanomaterial attributes of iron-carbohydrate nanoparticles: Leveraging orthogonal methods to resolve the 3-dimensional structure.
Krupnik L; Joshi P; Kappler A; Flühmann B; Alston AB; Digigow R; Wick P; Neels A
Eur J Pharm Sci; 2023 Sep; 188():106521. PubMed ID: 37423578
[TBL] [Abstract][Full Text] [Related]
3. Putting square pegs in round holes: Why traditional pharmacokinetic principles cannot universally be applied to iron-carbohydrate complexes.
Alston AB; Digigow R; Flühmann B; Wacker MG
Eur J Pharm Biopharm; 2023 Jul; 188():6-14. PubMed ID: 37142131
[TBL] [Abstract][Full Text] [Related]
4. Criticality of Surface Characteristics of Intravenous Iron-Carbohydrate Nanoparticle Complexes: Implications for Pharmacokinetics and Pharmacodynamics.
Funk F; Flühmann B; Barton AE
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216261
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Physicochemical Properties of the Iron Nanoparticle Drug Products: Brand and Generic Sodium Ferric Gluconate.
Brandis JEP; Kihn KC; Taraban MB; Schnorr J; Confer AM; Batelu S; Sun D; Rodriguez JD; Jiang W; Goldberg DP; Langguth P; Stemmler TL; Yu YB; Kane MA; Polli JE; Michel SLJ
Mol Pharm; 2021 Apr; 18(4):1544-1557. PubMed ID: 33621099
[TBL] [Abstract][Full Text] [Related]
6. Snapshots of Iron Speciation: Tracking the Fate of Iron Nanoparticle Drugs via a Liquid Chromatography-Inductively Coupled Plasma-Mass Spectrometric Approach.
Neu HM; Alexishin SA; Brandis JEP; Williams AMC; Li W; Sun D; Zheng N; Jiang W; Zimrin A; Fink JC; Polli JE; Kane MA; Michel SLJ
Mol Pharm; 2019 Mar; 16(3):1272-1281. PubMed ID: 30676753
[TBL] [Abstract][Full Text] [Related]
7. Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation.
Pai AB
Ann N Y Acad Sci; 2017 Nov; 1407(1):17-25. PubMed ID: 29027212
[TBL] [Abstract][Full Text] [Related]
8. Iron Treatment Strategies in Dialysis-Dependent CKD.
Pandey R; Daloul R; Coyne DW
Semin Nephrol; 2016 Mar; 36(2):105-11. PubMed ID: 27236131
[TBL] [Abstract][Full Text] [Related]
9. The intravenous use of high molecular ferric carbohydrate compound in the treatment of hypochromic anemia.
LUCAS JE; HAGEDORN AB
Blood; 1952 Mar; 7(3):358-67. PubMed ID: 14904518
[No Abstract] [Full Text] [Related]
10. Nanomedicines in clinical practice: Are colloidal iron sucrose ready-to-use intravenous solutions interchangeable?
Di Francesco T; Sublet E; Borchard G
Eur J Pharm Sci; 2019 Apr; 131():69-74. PubMed ID: 30742979
[TBL] [Abstract][Full Text] [Related]
11. Balance of Benefit and Risk in Intravenous Iron Treatment in Chronic Kidney Disease.
Fishbane S
Semin Nephrol; 2016 Mar; 36(2):119-23. PubMed ID: 27236133
[TBL] [Abstract][Full Text] [Related]
12. Differences between intravenous iron products: focus on treatment of iron deficiency in chronic heart failure patients.
Martin-Malo A; Borchard G; Flühmann B; Mori C; Silverberg D; Jankowska EA
ESC Heart Fail; 2019 Apr; 6(2):241-253. PubMed ID: 30694615
[TBL] [Abstract][Full Text] [Related]
13. Intravenous Iron-Carbohydrate Nanoparticles and Their Similars. What Do We Choose?
Mehedinti AM; Capusa C; Andreiana I; Mircescu G
Maedica (Bucur); 2022 Jun; 17(2):436-448. PubMed ID: 36032600
[TBL] [Abstract][Full Text] [Related]
14. New insights into iron deficiency and iron deficiency anemia.
Camaschella C
Blood Rev; 2017 Jul; 31(4):225-233. PubMed ID: 28216263
[TBL] [Abstract][Full Text] [Related]
15. The safety of available treatment options for iron-deficiency anemia.
Muñoz M; Gómez-Ramírez S; Bhandari S
Expert Opin Drug Saf; 2018 Feb; 17(2):149-159. PubMed ID: 29103332
[TBL] [Abstract][Full Text] [Related]
16. Iron polymaltose complexes: Could we spot physicochemical differences in medicines sharing the same active pharmaceutical ingredient?
Di Francesco T; Delafontaine L; Philipp E; Lechat E; Borchard G
Eur J Pharm Sci; 2020 Feb; 143():105180. PubMed ID: 31841697
[TBL] [Abstract][Full Text] [Related]
17. Regulatory challenges and approaches to characterize nanomedicines and their follow-on similars.
Mühlebach S; Borchard G; Yildiz S
Nanomedicine (Lond); 2015 Mar; 10(4):659-74. PubMed ID: 25723097
[TBL] [Abstract][Full Text] [Related]
18. Core size determination and structural characterization of intravenous iron complexes by cryogenic transmission electron microscopy.
Wu Y; Petrochenko P; Chen L; Wong SY; Absar M; Choi S; Zheng J
Int J Pharm; 2016 May; 505(1-2):167-74. PubMed ID: 27001529
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of intravenous iron administration for uterine bleeding or postpartum anaemia: a narrative review.
Daniilidis A; Panteleris N; Vlachaki E; Breymann C; Assimakopoulos E
J Obstet Gynaecol; 2018 May; 38(4):443-447. PubMed ID: 29057687
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and treatment of unexplained anemia with iron deficiency without overt bleeding.
Dahlerup JF; Eivindson M; Jacobsen BA; Jensen NM; Jørgensen SP; Laursen SB; Rasmussen M; Nathan T
Dan Med J; 2015 Apr; 62(4):C5072. PubMed ID: 25872536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
